| Congresso Brasileiro de Microbiologia 2023 | Resumo: 342-1 | ||||
Resumo:Ulcerative colitis, ulcerous colitis or ulcerative rectum colitis, is an inflammation limited to the mucosa, located most often from the rectum to the proximal colon. It’s believed that the main cause of ulcerative colitis is the continuous inflammation in the mucosa, which may cause ulcerations and bleeding. The current treatment of inflammatory bowel diseases is mainly based on the use of anti-inflammatory drugs, immunomodulators, nutritional supplements and surgery The potential use of probiotics in the prevention / treatment of inflammatory bowel diseases remains unclear. In this context. The use of probiotics in the treatment and prevention of diseases is a very current topic and presents itself as a very interesting therapeutic possibility. The objective of this work was to evaluate the effects of probiotic orange juice containing Pediococcus acidilactici CE51 in a murine model of colitis. A total of 45 male Swiss lineage mice were used, divided into five groups (n = 9): control, colitis, colitis + probiotic (probiotic orange juice containing CE51), colitis + placebo (orange juice) and colitis + sulfasalazine (10mg / kg /Weight). The induction of colitis was performed with dextran sodium sulfate (3%). The treatment time was 5 and 15 days after induction. Histopathological analysis, serious measurements of TNF-alpha and C-reactive protein and metagenomic analysis of feces were performed after euthanasia. Probiotic treatment reduced inflammation in the small intestine, large intestine and spleen. The probiotic did not alter the serum dosages of TNF-alpha and C-reactive protein. Their use maintained the quantitative ratio of the phylum Firmicutes / Bacteroidetes and increased Lactobacillus helveticus with 15 days of treatment (p <0.05). The probiotic orange juice containing Pediococcus acidilactici CE51 modulated the intestinal microbiota and attenuated the inflammation induced in colitis. Palavras-chave: Gut microbiota, Inflammatory bowel diseases, Pediococcus acidilactici CE51, Probiotic, Ulcerative colitis Agência de fomento:São Paulo Research Foundation - FAPESP (grant number 2018 / 14658–1 and 2020/12040-0) and University of Western São Paulo (grant #6884). | |||||